dipyridamole / Generic mfg. - LARVOL DELTA

ST Segment Depression at High Flow on Rubidium Myocardial Perfusion Imaging (SNMMI 2025) - "Purpose/Background: Over the past few years, we noticed that an unusually high proportion of patients suffering from angina with no obstructive coronary artery disease (ANOCA) referred for evaluation of coronary microvascular dysfunction (CMD) with Rubidium-82 positron emission tomography (82Rb-PET) myocardial perfusion imaging (MPI) exhibit ST segment depressions following administration of dipyridamole... ST segment depression was identified in 37 (5.5%, all females), including 12 ANOCA patients and 25 controls (8.8 vs 4.7%, p=0.089). sMBF and stress heart rate (HR) were significantly associated with ST depression in both groups (p3.5 mL/min/g were 37.5% and 16.7% in the ANOCA and control groups, respectively."

Cardiomyopathy • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Heart Failure • Mood Disorders • Psychiatry

SPECT myocardial blood flow using a rotating NaI gamma camera, multi- focal collimation and multi-modal reconstruction (SNMMI 2025) - "Stress was induced using a 0.56 mg/kg infusion of dipyridamole... Conclusion : It is feasible to obtain SPECT MBF measurements using a dual-head NaI rotating gamma camera with multi-focal collimators and multi-modal reconstruction. [1] Finnegan, RN, Chin, V, Chlap, P, et al. Open-source, fully-automated hybrid cardiac substructure segmentation: development and optimisation."

Heart Failure

Antiplatelet versus anticoagulation treatment for people with heart failure in sinus rhythm. (PubMed, Cochrane Database Syst Rev) - "There is some evidence from RCTs that OAC with warfarin compared to platelet inhibition with aspirin probably has little to no effect on mortality in people with systolic heart failure in sinus rhythm (moderate-certainty evidence). Treatment with warfarin probably reduces non-fatal cardiovascular events but probably increases the risk of major bleeding complications (moderate-certainty evidence). We saw a similar pattern of results for the warfarin versus clopidogrel comparison (low-certainty evidence). At present, there are no data on the role of OAC versus antiplatelet agents in heart failure with preserved ejection fraction in sinus rhythm. Also, there were no data from RCTs on the utility of non-vitamin K antagonist oral anticoagulants compared to antiplatelet agents in heart failure with sinus rhythm."

Clinical • Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Myocardial Infarction • Pulmonary Embolism • Respiratory Diseases

Relationship Between CFR and Impaired Left Ventricular Myocardial Reactivity in Patients with CMVD: An Applied Study Based on Adenosine/Dipyridamole and Exercise Stress Echocardiography (ChiCTR) - P=N/A | N=70 | Completed | Sponsor: Fuwai Yunnan Cardiovascular Hospital; Fuwai Yunnan Cardiovascular Hospital

New trial

Subclinical Augmentation in Relation to Previous Dopaminergic Treatment in Patients with Restless Legs Syndrome: A Post Hoc Analysis of Two Randomized, Placebo-Controlled, Crossover Trials. (PubMed, CNS Drugs) - "Our results suggest that previous long-term dopaminergic treatment, even before clinical augmentation is reached, induces pathophysiological changes in RLS that impair future responses to both dopaminergic and non-dopaminergic therapies. Our findings confirm previous results with gabapentin enacarbil and suggest that these changes develop well before clinical augmentation appears. Pathophysiological implications for the understanding of dopaminergic augmentation are discussed. Our results support the American Academy of Sleep Medicine (AASM) recommendation against using dopamine agonists as the initial choice for RLS treatment."

Journal • Retrospective data • Movement Disorders • Restless Legs Syndrome • Sleep Disorder

Novel treatment with dipyridamole counteracts the sarcopenic footprint in experimental RA via increase of adenosine levels and A2A/A2BR activation (EULAR 2025) - "Dipyridamole demonstrates potential as a therapeutic agent for counteracting sarcopenia in RA by modulating adenosine levels and activating A2BR signaling, offering a promising approach to managing the sarcopenic footprint in these patients."

Fibrosis • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Sarcopenia • CDKN1A • CRP • FBXO32

Dipyridamole prevents the metabolic switch caused by rheumatoid arthritis in muscle by purinergic system modulation (EULAR 2025) - "RA causes a metabolic switch, with insulin resistance and altered glucose control, translating fatty acids as the main source of energy in muscle. Treatment with dipyridamole prevented this metabolic state promoting glucose use."

Cachexia • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Sarcopenia • FABP3 • IL6 • NRF1 • PDK4 • SLC2A4 • TFAM

Allopurinol associated cardiovascular risk and protective effect of colchicine in gout patients: a Dutch nationwide pharmaco-epidemiologic cohort study. (EULAR 2025) - "A CV event was defined as a new dispensed prescription for a platelet aggregation inhibitor (clopidogrel, prasugrel, ticagrelor or dipyridamole). After allopurinol start – especially the first 30 to 90 days - there is a dose-dependent increase in the risk of cardiovascular risk, which is fully countered by concomitant colchicine use. Discontinuation of allopurinol does not lead to a relevant increase in cardiovascular event risk. Concomitant use of colchicine or slower dose escalation of allopurinol seems prudent to decrease the risk of CV events in gout patients starting allopurinol."

Clinical • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Gout • Heart Failure • Hypertension • Inflammatory Arthritis • Rheumatology

Extracellular inosine induces anergy in B cells to alleviate autoimmune hepatitis. (PubMed, Cell Mol Gastroenterol Hepatol) - "Our findings revealed that inosine was a crucial metabolite that induced immune tolerance of B cells, thus proposing a potential intervention strategy for AIH."

Journal • Autoimmune Hepatitis • Immunology • Inflammation • CD73 • NT5E • SLC29A1 • STAT6

Computer-driven formulation development of dipyridamole dry nanosuspension. (PubMed, Int J Pharm) - "In conclusion, our study successfully developed a DIP dry nanosuspension with improved dissolution and bioavailability, specifically tailored for pediatric use. The combination of computational and experimental methods offers a strong foundation for future formulation development, significantly reducing both time and costs."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pediatrics

PACIFIC-PFO: Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study (clinicaltrials.gov) - P=N/A | N=1000 | Not yet recruiting | Sponsor: National University Hospital, Singapore

New trial • Cardiovascular • Ischemic stroke

Prognostic significance of coronary flow velocity reserve in patients with peripheral arterial disease. (PubMed, Int J Cardiovasc Imaging) - "In patients with PAD, SE shows more than 4-fold higher prevalence of abnormal CFVR compared to RWMA. The prognostic value of CFVR outperforms RWMA, showing the importance of coronary microvascular dysfunction and diffuse, subcritical coronary atherosclerosis in determining the outcome."

Clinical • Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders • Peripheral Arterial Disease

Harnessing FDA-approved dipyridamole to inhibit NLRP3 inflammasome and improve outcomes of acute lung injury in sepsis. (PubMed, Toxicol Appl Pharmacol) - "Additionally, Dipyridamole effectively inhibited NLRP3 inflammasome activation in lung tissue. These findings position Dipyridamole as a potent NLRP3 inflammasome inhibitor with substantial therapeutic potential for managing sepsis-induced ALI."

FDA event • Journal • Acute Lung Injury • Infectious Disease • Inflammation • Respiratory Diseases • Septic Shock • NLRP3

Dipyridamole Acts as Clinical Ferroptosis Inhibitor to Prevent from Tissue Injury. (PubMed, Adv Sci (Weinh)) - "Numerous studies reveal that ferroptosis participates in multiple types of tissue injury including ischaemia-reperfusion (I/R) injury and doxorubicin (Dox)-induced damage. Deficiency of SLC7A11 largely blocks the protective role of dipyridamole in vitro and in vivo. Together, the findings uncover that dipyridamole acts as a clinical compound to alleviate organ injury via suppressing ferroptosis, providing novel insights into the clinical therapy for ferroptosis-related tissue damage."

Journal • Renal Disease • Reperfusion Injury • Targeted Protein Degradation • SLC7A11

Tailoring dual antiplatelet therapy for stroke prevention: a meta-analysis of timing, duration, regimen, and stroke subtypes. (PubMed, Front Pharmacol) - "Subgroup analysis examined the effectiveness of DAPT versus any single antiplatelet therapy, stratified by stroke type (ischemic stroke, lacunar stroke, and TIA or ischemic stroke), timing of intervention onset (within 12 h, 24 h, 48 h, 72 h, and 7-180 days), duration of DAPT (short-term: up to 30 days; long-term: beyond 30 days) and DAPT regimens (Aspirin and Clopidogrel, Aspirin and Cilostazol, Aspirin and Dipyridamole, and Clopidogrel and Cilostazol, etc.). Short-term DAPT (≤30 days) may be optimal for recurrent stroke prevention. Clinicians should carefully weigh benefits and risks when personalizing DAPT strategies."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Ischemic stroke

Fabrication of Radiopaque, Drug-Loaded Resorbable Polymer for Medical Device Development. (PubMed, Polymers (Basel)) - "Poly-p-dioxanone (PPDO) sutures were infused with gadolinium nanoparticles (GdNPs) and dipyridamole (DPA), an anti-thrombotic agent...Clot-trapping efficacy was maintained, and no hemolysis or cellular toxicity was observed. In conclusion, the GdNP- and DPA-infused PPDO IVCFs demonstrated improved radiopacity, anti-thrombotic potential, and compatibility with routine imaging, without compromising mechanical strength or safety."

Journal • Cardiovascular • Hematological Disorders • Pulmonary Embolism • Respiratory Diseases

Risk of Complications Following Medialization Thyroplasty in Patients on Anticoagulation (COSM 2025) - "Patients taking AC/AP (aspirin, warfarin, apixaban, edoxaban, rivaroxaban, dabigatran, dipyridamole, ticagrelor, prasugrel, clopidogrel, cilostazol, dalteparin, enoxaparin) within 1 month of the procedure were identified and compared to those not taking these medications. Based on analysis of a large healthcare database, MT performed on AC/AP is associated with higher rates of post-operative dysphagia and airway compromise but not postoperative hemorrhage/hematoma."

Clinical • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease

A potential supplemental indication of dipyridamole for contraception: Dipyridamole inhibits mouse sperm fertilization capacity in vitro. (PubMed, Biochem Biophys Res Commun) - "These results suggest that dipyridamole at therapeutic doses could have contraceptive or adverse effects in men if the medication produces similar inhibitory effect on human sperm functions. Currently, however, there have been no reports of contraceptive or adverse effects in men taking dipyridamole, although it is possible that most men are past the normal reproductive age when taking this antiplatelet medication."

Journal • Preclinical

Targeting the CD39/CD73 pathway: New insights into cardiac fibrosis and inflammation in female cardiac surgery patients. (PubMed, J Mol Cell Cardiol Plus) - "Increased CD73 function (via dipyridamole) decreased fibrosis. This study demonstrates the importance of purinergic dysfunction in cardiovascular disease in women and presents two potential therapeutics to improve cardiac health via manipulation of purine pathways."

Journal • Cardiovascular • Fibrosis • Immunology • Inflammation • CD73 • ENTPD1 • NT5E

Efficacy and safety of antiplatelet therapy for secondary prevention of small subcortical infarction: A systematic review and network meta-analysis. (PubMed, Eur Stroke J) - "Cilostazol may be the most effective agent for preventing cardiovascular event recurrence. Aspirin plus clopidogrel and vorapaxar may be not recommended due to heightened bleeding risks."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Ticagrelor or dipyridamole plus aspirin may be a promising antiplatelet therapy in patients with minor stroke or transient ischemic attack: a bayesian network meta-analysis. (PubMed, Front Pharmacol) - "Ticagrelor + Aspirin was significantly more effective than Clopidogrel + Aspirin in preventing post-stroke neurological dysfunctions (mRS 0-1), recurrent stroke and major vascular events for up to 90 days. Due to limited studies, the superiority of Dipyridamole + Aspirin is still difficult to conclude, and further high-quality studies are needed to verify the benefits of Dipyridamole + Aspirin in minor stroke or TIAs. https://www.crd.york.ac.uk/prospero/, identifier CRD42024537462."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • CYP2C19

Therapeutic Dosing and Stability of Anti-Platelet Agents in Pediatric Ventricular Assist Device Patients (ISHLT 2025) - "Post-VAD, all patients were started on aspirin and dipyridamole (one switched to clopidogrel) between days 4-14. Additionally, there are significant fluctuations in values with sub-optimal maintenance of therapeutic effect. This may represent clinical decision making, practice variations, patient factors or testing variations and warrants further study."

Clinical • Cardiomyopathy • Cardiovascular • Heart Failure • Pediatrics

WHAT IS THE CULPRIT: MITRAL VALVE STRANDS IN A YOUNG PATIENT WITH CEREBRAL ISCHEMIA - Subhiksha Aravind (ACC 2025) - "Very few case reports illustrate an association between cerebral ischemia and valvular strands. Even though it remains controversial, studies reveal resolution of the strands after institution of anticoagulation with warfarin or the addition of dipyridamole to warfarin​. Recognition of mitral valve strands in diagnosis of stroke would be imperative in order to determine if patient would benefit from anticoagulation to prevent recurrence of stroke​"

Clinical • Cardiovascular • Diabetes • Hematological Disorders • Ischemic stroke • Metabolic Disorders • Thrombosis

In Vivo Animal Spices and Experimental Technique to Evaluate Sustained Release Granules. (PubMed, Biopharm Drug Dispos) - "To clarify the best animal and/or experimental technique for the evaluation of modified release formulations, we investigated dipyridamole pharmacokinetics from prototype sustained release granules by utilizing beagle dogs, propantheline bromide-treated (PBT) beagle dogs, and miniature pigs...However, in PBT dogs, a sustained release effect was observed in the 45 mg sustained release granule, and its bioavailability was also maintained. Accordingly, PBT dogs could be the best to evaluate sustained release formulations such as tablets and granules, and the use of miniature pigs might be better to evaluate granules with equal to or less than 1 mm diameter."

Journal • Preclinical

Artificial gut Simulator. A scheme to predict intestinal and plasma concentration-time profiles of a weakly basic BCS-II drug, dipyridamole. (PubMed, Eur J Pharm Biopharm) - "For 30 and 90 mg oral doses, time profiles of concentration and fraction precipitated in the AGS donor agreed well with human duodenal measurements. This study demonstrates the significance of simulating physiological rate of absorption in vitro to accurately predict the bioavailability of a BCS-II compound."

Journal